Articles tagged with Alzheimer Disease
A study published in Health Economics found that individuals with early-stage Alzheimer's disease face a heightened risk of adverse financial outcomes due to compromised decision-making and exploitation. The researchers tracked financial data before diagnosis and found significant reductions in liquid assets and net wealth.
A UB researcher's study using 26,000 books suggests that the learning environment plays a significant role in shaping language behavior. The researchers analyzed data from 10 different studies involving over 1,000 participants and found that culture-specific books explained much of the variance in the data.
Researchers at Medical University of South Carolina discover a protein P17/PERMIT that regulates mitochondrial function and could be a connection between age-related diseases. The protein helps recycle aging mitochondria, which can contribute to conditions like cancer and Alzheimer's.
A new study found that people with dementia whose parents also had dementia develop symptoms an average of six years earlier. Factors such as education and genetic variants accounted for less than a third of the variation in age at onset, suggesting more to be discovered about the factors affecting when symptoms arise.
A study of 526 older adults found that hospitalizations accelerated cognitive decline, especially for those with more brain pathology. The research suggests that having Alzheimer's-related changes in the brain is bad enough, but being hospitalized adds insult to injury.
Research at MIT's Picower Institute has shown that stimulating a specific brain rhythm via light or sound can reduce amyloid buildup and improve memory in Alzheimer's model mice. The technique, called GENUS, also shows promise in reducing inflammation and improving blood vessel function.
Studies show intestinal bacterial imbalance linked to neurodegenerative diseases like Alzheimer's Disease and traumatic brain injury. Probiotics may improve brain function by altering the gut microbiome, reducing amyloid beta plaque and memory deficits.
Researchers discovered 48 genetic variations associated with brainstem and subcortical structure volumes, including those related to diseases like Alzheimer's and Parkinson's. The study's findings may lead to novel drug targets for treating these conditions.
New approaches in transcriptomics are providing single cell views of brain development and disease, including cellular processes associated with addiction and degeneration. These studies highlight the potential of transcriptomics to probe molecular changes within brain cells during normal development or diseases such as Alzheimer's and...
Researchers found gene therapy potential in treating neurological disorders like Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. New therapeutic approaches reprogram glial cells into motor neurons and deliver antibodies to protect against toxins.
Research reveals a connection between Alzheimer's disease and metabolic disturbances, including glucose resistance and abnormal sleep patterns. Introducing ApoE2 into cells expressing ApoE4 may reduce metabolic deficiencies, supporting cellular functions and energy metabolism in the brain.
Researchers found metabolic defects precede amyloid-beta protein accumulation in Alzheimer's disease. Treatment with Metformin reversed these defects and improved healthspan and lifespan in a tiny worm model.
Kent State University's Gemma Casadesus Smith receives a new two-year NIH grant to investigate the relationship between diabetes, obesity, and Alzheimer's disease. Her research aims to identify early genetic changes and brain transcriptome shifts that contribute to Alzheimer's development.
A new study at Rush University Medical Center aims to determine whether a combination of lifestyle changes can protect memory and thinking skills in people at risk of developing dementia. The two-year U.S. POINTER clinical trial will enroll 2,000 adults between 60-79 years old with no current memory problems or exercise habits.
Scientists have linked abnormal tau in the brain to at least 25 neurodegenerative diseases, but current diagnosis requires analyzing brain tissue after death. The new test uses cerebrospinal fluid to detect abnormal tau, offering hope for diagnosing less common neurological diseases like Alzheimer's.
Researchers have created a mouse model with a fully replaced human version of the MAPT gene, allowing for accurate genetic therapy development and evaluation. This breakthrough enables scientists to study the role of the human version of the gene in humans and develop therapies.
A new international study has discovered epigenetic marks in Finnish twin pairs discordant for Alzheimer's disease, which were also found in brain samples of patients. These marks are influenced by environmental factors, age, gender, and APOE genotype, and have potential diagnostic applications.
A new study found that brain immune cells called microglia drive brain damage in Alzheimer's patients. Eliminating these cells reduces tau-linked brain damage, suggesting a potential therapeutic target.
A nationwide, multiple-site study will investigate whether lifestyle changes can improve chronic sleep problems, which have been linked to an increased risk of cognitive decline and Alzheimer's disease. The study aims to identify an effective strategy for improving sleep that could prevent Alzheimer's disease and related dementias.
Researchers analyzed Toronto resident Vivian White's diary entries from 1985 to 2016, finding a significant relationship between language changes and cognitive decline. After being diagnosed with Alzheimer's at age 84, White included the first-person pronoun 'I' consistently in her writing.
A new study led by a University of Miami neurologist found that sleep disturbances among Hispanics may increase their risk of cognitive impairment and Alzheimer's disease. Insomnia and prolonged sleep duration were linked to declines in memory, executive function, and processing speed, which can precede the onset of dementia.
Using sex-specific scores on memory tests may change who gets diagnosed with mild cognitive impairment (MCI) by 20 percent, with possibly more women and fewer men being diagnosed. The study found that using the sex-specific scores resulted in a higher diagnosis rate for women, while lower rates for men.
Tymora Analytical Operations is developing a plasma-based approach for early detection of Alzheimer's disease. The company aims to analyze exosome proteins and phosphoproteins in plasma samples to identify biomarkers linked to the disease.
Researchers found that aggregates of tau protein disrupt RNA splicing, leading to global disruptions in brain cells. This discovery presents an exciting new possibility for using RNA splicing as a potential target for Alzheimer's disease treatment.
A new study quantifies the strength of relationship between playing American football and chronic traumatic encephalopathy (CTE) severity. The study found that each additional year played increased CTE risk by 30% and severe CTE odds doubled for every 5.3 years played.
A new study from the University of Eastern Finland found that people with Alzheimer's disease who used antipsychotic drugs accumulated more hospital days over a two-year period. The study, based on the MEDALZ cohort, found that antipsychotic initiators had approximately eleven more hospital days per person-year compared to non-initiators.
A new $2.8 million grant will support a preclinical efficacy study of MW150, a potential treatment for dementia. The drug targets dysregulated brain inflammation driven by p38-MAPK, which is also linked to vascular cognitive impairment and dementia.
Research investigates how diet and excess blood glucose influence Alzheimer's pathology, providing new insights into the link between diabetes and Alzheimer's disease. The study aims to develop therapies targeting glucose pathways, offering potential treatments for this debilitating condition.
The National Institute on Aging announced winners of its Eureka competition, which aims to spur technological innovations in dementia care. MapHabit took first place with a mobile app helping people with dementia follow simple commands and receive feedback from caregivers.
A study published in Journal of the American College of Cardiology shows that oral anticoagulant dabigatran slows Alzheimer disease progression in mice by improving cerebral circulation. The treatment reduces typical symptoms like inflammation and amyloid protein plaques.
A new study by MIT neuroscientists pinpointed the earliest emergence of amyloid protein plaques in the human brain, finding they correlate strongly with disease progression. The research uses a mouse model to track plaque development and shows that these regions eventually spread throughout the brain.
Experts recommend promoting a 'brain-healthy lifestyle' through public education campaigns, research programs, and healthcare system preparedness. This can help reduce the risk of developing neurodegenerative diseases by emphasizing that healthy habits are generally good for brain health.
MIT researchers are developing a multicellular integrated chip platform to model the complexity of Alzheimer's disease. They will integrate blood vessels and key cell types, including neurons, immune cells, and oligodendrocytes, to provide a powerful testbed for personalized research.
The National Institute on Aging has awarded a grant to establish the Open-AD Drug Discovery Center, which aims to accelerate the development of new drugs for Alzheimer's disease. The center will develop research platforms and openly distribute tools to test the efficacy of Alzheimer's therapies.
Scientists have identified a key role for the brain protein TOM-1 in regulating inflammatory responses, which are linked to Alzheimer's disease. By restoring TOM-1 levels, the study found improved pathology and cognitive problems associated with the disease.
The IU-led center will focus on proteins related to the brain's immune system that may contribute to Alzheimer's disease. The goal is to develop high-quality research tools and new technologies needed to broaden the number of targets being investigated for effective medicines.
A study published in the journal Aging Cell found that a lifelong dietary regimen of choline can improve spatial memory and reduce AD-like symptoms in female mice. Choline supplementation also reduces microglia activation, offering protection from brain inflammation and neuronal death.
An observational study of 3,021 adults aged 72 and older found that alcohol consumption was not significantly associated with an increased risk of dementia in those without mild cognitive impairment. However, among those with MCI, drinking more than 14 drinks per week was linked to the highest risk of dementia
University of Warwick researchers introduce fluorescently labelled Tau oligomers into single brain neurons and observe significant effects on action potential dynamics and synaptic transmission. They find that Tau oligomers interfere with memory storage by mis-localising at synapses.
Researchers discovered novel brain circuits in the hippocampal formation play a critical role in object-location learning and memory. The study provides new insights into Alzheimer's disease, offering potential targets for treatment.
Researchers at Newcastle University found that people with Alzheimer's disease and Lewy body dementia have unique walking patterns that signal subtle differences between the two conditions. Analyzing step length variability and step time asymmetry can accurately identify 60% of all dementia subtypes.
Researchers will image protein structures at an atomic scale, gaining insight into disease mechanisms and developing new diagnostic and treatment strategies for Alzheimer's, Parkinson's, and Lewy body dementia.
Researchers have discovered two short peptides that significantly improved memory and reduced physical changes in the brain of mice with Alzheimer's disease. The treatment uses a process of computer modeling and artificial intelligence to develop an optimized oral version of the drug, which could lead to new treatments for Alzheimer's.
A University of Houston chemist is investigating the role of copper in neurodegenerative diseases like Alzheimer's. The researcher aims to understand how cells regulate copper levels, which are found to be unusually high in people with the disease.
A commonly used Alzheimer's treatment, donepezil, significantly increases the risk of hospitalization for rhabdomyolysis, a serious condition that can cause kidney damage. The study found a two-fold higher risk of hospitalization with donepezil compared to other cholinesterase inhibitors.
A new study reveals that a protein called caveolin-1 (Cav-1) is depleted in the temporal lobe of humans with type-2 diabetes and in a diabetic mouse model, leading to increased Alzheimer's disease pathology. Restoring Cav-1 levels in mice reduced Alzheimer's pathology and improved learning and memory deficits.
A new study reveals that APOE4, the strongest genetic risk factor for Alzheimer's disease, impairs the function of human brain immune cells, microglia. This impairment increases inflammation and reduces their ability to remove toxic amyloid from the brain.
Researchers at the Complutense University of Madrid have identified areas of the retina that change in patients with mild Alzheimer's disease. The study used optical coherence tomography to measure retinal layer thickness and found significant thinning in certain locations, which can be used to diagnose the disease before other tests.
Researchers found that people with mild cognitive impairment may have different brain changes depending on the type of dementia they have. The study suggests that these changes could potentially be used to track early changes in Alzheimer's disease and cerebrovascular disease.
Calcium channel blockers reduced calcium ion flow into brain cells, restoring normal function and improving memory in diseased flies. The study suggests targeting L-type channels could be effective in treating Alzheimer's memory loss.
The proposed framework assesses multiple brain-body interactions contributing to Alzheimer's disease, including environmental and genetic factors. Gene-environment interactions are shown to shift the onset curve of dementia by 10 years in carriers of dominant Alzheimer's genes.
A new study suggests that measuring how quickly a person's pupils dilate during cognitive tests may be a viable method for detecting Alzheimer's disease risk before symptoms appear. The study links pupillary dilation responses to identified AD risk genes, providing proof-of-concept for this screening tool.
Researchers at Brown University and Hebrew SeniorLife will create a collaborative research incubator to support trials aimed at improving care for people living with dementia. The grant will fund up to 40 pilot projects that test non-drug, care-based interventions.
Researchers have identified a novel biomarker for dementia, IGFBP-2, which is associated with an increased risk of all-cause dementia and Alzheimer's disease. Elevated circulating levels of IGFBP-2 significantly improved dementia risk classification when added to traditional risk factors.
A new drug, BPN14770, has shown promise in protecting against memory loss and nerve damage associated with Alzheimer's disease. The drug inhibits phosphodiesterase 4D, an enzyme that plays a key role in memory formation and neuroinflammation.
Research linking migraines to increased risk of dementia highlights the importance of early detection and prevention strategies for Alzheimer's disease. Migraines were identified as a mid-life risk factor for dementia, including Alzheimer's disease, in a study of 679 community-dwelling adults aged 65 years and older.
Researchers found that nearly all dementia diagnoses were made by non-specialist physicians, leading to missed opportunities for more accurate diagnosis and targeted treatment. The study highlights the need for better training and tools for primary care doctors to diagnose dementia subtypes.
Researchers found that maladaptive changes in calcium transport by mitochondria contribute to the progression of Alzheimer's disease. Altering NCLX expression and mitochondrial calcium homeostasis restored cognitive function and reduced amyloid beta and tau pathology.
Researchers found a modified Mediterranean-ketogenic diet altered gut microbiome and reduced Alzheimer's markers in participants with mild cognitive impairment. The study suggests that specific gut bacteria changes may impact dementia development.
Researchers found that resistance to ghrelin hormone is linked to cognitive impairments and memory loss in Alzheimer's disease. Activating both ghrelin and dopamine receptors simultaneously may help restore brain function and reduce lesions.